文献速递腹部技术与安全CT

评估胰腺导管腺癌化疗反应:单源双能CT碘浓度与CT值的直方图分析

Assessing Chemotherapeutic Response in Pancreatic Ductal Adenocarcinoma: Histogram Analysis of Iodine Concentration and CT Number in Single-Source Dual-Energy CT.
PubMed 文献 · AJR Am J Roentgenol · 2018-10-17

前瞻性纳入60例接受一线化疗但未放疗的胰腺导管腺癌患者,于胰腺实质期和平衡期行单源双能CT,测量碘浓度与CT值并行直方图分析。胰腺实质期碘浓度峰度和两期碘浓度差值可区分反应组与无反应组,联合诊断因子敏感度97.7%、特异度70.6%、AUC 0.889。

要点

  • 胰腺实质期碘浓度峰度(P=0.018)和两期碘浓度差值(P=0.0004)在反应组与无反应组间有显著差异。
  • 碘浓度诊断因子敏感度97.7%、特异度70.6%、AUC 0.889,用于区分部分缓解/稳定与进展。
  • 诊断因子公式为0.52-(1.45×胰腺实质期碘浓度峰度)+(0.69×两期碘浓度差值)。

核心结论

  • 碘浓度诊断因子可能是评估胰腺导管腺癌患者化疗反应的潜在生物标志物。

研究设计与样本

  • 前瞻性研究,纳入60例连续接受一线化疗但未放疗的胰腺导管腺癌患者,行单源双能CT胰腺实质期和平衡期扫描,以实体瘤疗效评价标准分为反应组(部分缓解或稳定)与无反应组(进展)。

关键影像表现/征象

  • 在胰腺实质期碘图上测量胰腺导管腺癌的碘浓度,在65 keV单能图像上测量CT值,并获取二者的直方图参数。
  • 计算胰腺实质期与平衡期之间的平均碘浓度差值(ΔIC)和CT值差值(ΔHU)。
  • 胰腺实质期碘浓度峰度(P=0.018)和ΔIC(P=0.0004)在反应组与无反应组间差异有统计学意义。

诊断标准与关键数值

  • 碘浓度诊断因子=0.52-(1.45×胰腺实质期碘浓度峰度)+(0.69×ΔIC)。
  • 该诊断因子区分反应组与无反应组的敏感度97.7%、特异度70.6%、AUC 0.889。

临床应用与阅片要点

  • 作者认为碘浓度诊断因子可能是评估胰腺导管腺癌化疗反应的潜在生物标志物。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: The objective of this study was to evaluate the feasibility of histographic analysis of iodine concentration (IC) and CT number on single-source dual-energy CT (DECT) to assess response to first-line chemotherapy in patients with pancreatic ductal adenocarcinoma (PDAC) who received first-line chemotherapy but not radiation therapy.

SUBJECTS AND METHODS: This prospective study was approved by our institutional review board, and patients gave written informed consent. Sixty consecutive patients with PDAC undergoing first-line chemotherapy underwent DECT during the pancreatic parenchymatous phase (PPP) and the equilibrium phase (EP). The IC and CT number of PDAC were measured using PPP and EP iodine-based material decomposition and monochromatic images (65 keV), respectively. Histographic parameters for the IC and CT number of PDACs were obtained, and differences in mean IC (ΔIC) and CT number (ΔHU) between the PPP and the EP were calculated. These parameters were then compared between the response (partial response or stable disease) and nonresponse (progressive disease) groups.

RESULTS: Among the histographic parameters, the kurtosis of IC during the PPP (p = 0.018) and ΔIC (p = 0.0004) were identified as significant for differentiating between the two groups. IC diagnostic factor was calculated using the following coefficients of logistic regression analysis: 0.52 - (1.45 × kurtosis of IC during PPP) + (0.69 × ΔIC). The sensitivity, specificity, and area under the ROC curve for differentiating between the two groups were 97.7%, 70.6%, and 0.889, respectively.

CONCLUSION: The IC diagnostic factor is a potential biomarker for assessing chemotherapeutic response in patients with PDAC.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Noda Y, Goshima S, Miyoshi T, et al. Assessing Chemotherapeutic Response in Pancreatic Ductal Adenocarcinoma: Histogram Analysis of Iodine Concentration and CT Number in Single-Source Dual-Energy CT. AJR Am J Roentgenol. 2018. PMID: 30332288. doi:10.2214/AJR.18.19791

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。